title: Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction.
abstract: BACKGROUND
  This study examined feasibility and safety of granulocyte colony-stimulating factor (G-CSF) treatment for patients with acute myocardial infarction (AMI).
  
  
  METHODS
  Forty patients with AMI related with the left anterior descending coronary artery, who underwent successful percutaneous coronary intervention (PCI), were randomized into G-CSF group (n=18) or Control group (n=22). G-CSF treatment was started within 24 h after PCI. 99mTc-tetrofosmin single-photon emission computed tomography (SPECT) was performed at 4 days and 6 months after AMI. SPECT data was analyzed for LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV ejection fraction (LVEF) and myocardial perfusion.
  
  
  RESULTS
  LVEF at 6 months was significantly better than that at 4 days in G-CSF group (p=0.013), but not changed in Control group (p=0.245). Although no significant difference was observed for LVEDV between the two groups, LVESV tended to be decreased only in G-CSF group. In G-CSF group, defect score (DS) was significantly decreased from 4 days to 6 months after AMI. Restenosis rate at 6 months after AMI was not significantly different between the two groups.
  
  
  CONCLUSIONS
  G-CSF treatment for patients with AMI was effective and did not have any clinical and angiographic adverse effects.
authors.affiliation: Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takano
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hasegawa
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kuwabara
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakayama
authors.forename: Koki
authors.initials: K
authors.lastname: Matsuno
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Masashi
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: Hisayuki
authors.initials: H
authors.lastname: Okada
authors.forename: Shinji
authors.initials: S
authors.lastname: Okubo
authors.forename: Miwa
authors.initials: M
authors.lastname: Fujita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shindo
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Komiyama
authors.forename: Noboru
authors.initials: N
authors.lastname: Takekoshi
authors.forename: Kamon
authors.initials: K
authors.lastname: Imai
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Himi
authors.forename: Iwao
authors.initials: I
authors.lastname: Ishibashi
authors.forename: Issei
authors.initials: I
authors.lastname: Komuro
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000628:therapy*; D011446:Prospective Studies; D011859:Radiography; D011877:Radionuclide Imaging; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor